Research location

Tianjin

Tianjin Municipality, China

Published trials579

Site observations717

Linked trials published579

Page1 / 12

Research activity in Tianjin

Tianjin Municipality, China

CureCurrent currently publishes aggregate city-level research activity for this location: 579 trials and 717 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Tianjin

579 linked trials · page 1 of 12

NK Cells Plus ICI for SCLC MaintenanceNCT07759856 · 2026-08-01 · 1 site observation

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15 · 1 site observation

Temporal Interference Stimulation Treatment in Patients With Cognitive ImpairmentNCT07643363 · 2026-07-01 · 1 site observation

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUreNCT07687186 · 2026-06-22 · 3 site observations

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 · 2026-05-05 · 1 site observation

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureNCT07528274 · 2026-05-01 · 1 site observation

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.NCT07593027 · 2026-04-30 · 2 site observations

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)NCT07496372 · 2026-04-30 · 1 site observation

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.NCT07450599 · 2026-04-27 · 1 site observation

Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07464587 · 2026-04-14 · 2 site observations

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerNCT07407283 · 2026-04-08 · 1 site observation

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)NCT07416474 · 2026-04-03 · 2 site observations

Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient AdherenceNCT07817056 · 2026-04-01 · 1 site observation

Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint PainNCT07490938 · 2026-04-01 · 1 site observation

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsNCT07589205 · 2026-03-31 · 1 site observation

A Phase II Trial of G01 Eye Drops for Glaucomatous Optic NeuropathyNCT07777861 · 2026-03-18 · 1 site observation

Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)NCT07386015 · 2026-02-28 · 1 site observation

A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionNCT07367529 · 2026-02-26 · 1 site observation

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerNCT07358676 · 2026-02-01 · 1 site observation

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based ChemotherapyNCT07548060 · 2026-02-01 · 1 site observation

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected IndividualsNCT07433387 · 2026-01-29 · 1 site observation

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes MellitusNCT07303803 · 2026-01-01 · 1 site observation

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesNCT07143045 · 2025-12-29 · 1 site observation

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesNCT07304739 · 2025-12-22 · 2 site observations

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 2 site observations

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267 · 2025-12-11 · 1 site observation

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)NCT07262645 · 2025-12-10 · 3 site observations

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerNCT07230106 · 2025-12-08 · 1 site observation

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229 · 2025-12-02 · 1 site observation

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant ChemoimmunotherapyNCT07330037 · 2025-12-01 · 1 site observation

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLCNCT07330050 · 2025-12-01 · 1 site observation

Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLCNCT07239661 · 2025-11-30 · 1 site observation

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerNCT07217301 · 2025-11-26 · 1 site observation

A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological MapsNCT07244094 · 2025-11-15 · 1 site observation

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerNCT07198633 · 2025-11-05 · 1 site observation

[18F]NIDF PET Imaging in Tau-related DiseasesNCT07306598 · 2025-11-01 · 1 site observation

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastasesNCT07469267 · 2025-10-24 · 1 site observation

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerNCT07100106 · 2025-10-07 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)NCT07179783 · 2025-09-22 · 1 site observation

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerNCT07043725 · 2025-09-15 · 2 site observations

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 2 site observations

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsNCT07169994 · 2025-09-02 · 1 site observation

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS PatientsNCT06880380 · 2025-09-01 · 1 site observation

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 · 2025-08-21 · 1 site observation

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19 · 1 site observation

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerNCT06868485 · 2025-08-18 · 1 site observation

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)NCT07079475 · 2025-07-30 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.